From the BIND article on YHOO: “Up to this point, biological barriers present in the human body, such as the intestinal epithelial lining, the blood brain barrier, and the mucosa of the lungs and eyes, have hindered absorption of nanoparticles. By targeting the neonatal Fc receptor, our founders have demonstrated the ability to successfully engineer targeted therapeutic nanoparticles that cross biological barriers and enter the bloodstream at therapeutic levels, which we believe could pave the road for opportunities for Accurin therapeutics for a myriad of other biological applications"
New target by end of first quarter and this should be much higher than 15 by then
I see this retracing back to it's offer price, which was reasonable considering the market..and then up to 15-20 and into hold pattern until the have some clinical news late in 2014..it will up and down with the biotech stocks until then. There may also be a dip in March when the 6 month holding period expires..depending on how things are going , it may be worth buying more then.